ArticleScientific reports2025
Characterization of the effects of oxymatrine on myocardial hypertrophy in spontaneously hypertensive rats through transcriptomics and metabolomics.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering macromolecular crowding-driven amyloid-mineral hybrid scaffolds for enhanced bone regeneration.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cardiac hypertrophy is a cardiac structural remodeling and dysfunction resulting from chronic hypertension and is an independent risk factor for cardiovascular morbidity and mortality. Oxymatrine (OMT), an alkaloid extracted from the traditional Chinese medicine Sophora flavescens, can ameliorate cardiac hypertrophy and heart failure. However, the underlying mechanisms remain unclear. In this study, we investigated the underlying mechanism of OMT on cardiac hypertrophy in spontaneously hypertensive rats (SHRs). Echocardiography was used to assess cardiac function of SHRs. Wheat germ agglutinin (WGA) and Masson staining were employed to evaluate the effects of OMT on cardiac fibrosis and cardiomyocyte hypertrophy in SHRs. Transcriptomics and metabolomics were performed to explore the underlying mechanisms of OMT's improvement of cardiac hypertrophy. The results were further verified by RT-qPCR, immunohistochemistry, and ELISA. The results show that OMT significantly alleviates myocardial hypertrophy and improves myocardial remodeling in SHRs, as evidenced by reduced left ventricular wall thickness, myocardial enlargement and collagen deposition. Transcriptomic analysis revealed that OMT reversed the expression of 10 genes associated with linoleic acid/arachidonic acid metabolism, cytochrome P450, steroid hormone biosynthesis, and myocardial adrenergic signaling. Metabolomic analysis indicated that OMT reversed the levels of 16 metabolites related to steroid hormone biosynthesis, aldosterone synthesis and secretion, and tryptophan metabolism. Integrated analysis revealed that the gene Cyp2e1 and the metabolite desoxycortone (DOC) were enriched in overlapping transcriptomic and metabolomic KEGG pathways, and both were reversed by OMT treatment. Our study underscores the potential molecular and metabolic mechanisms of OMT against pressure overload-induced myocardial hypertrophy and provides theoretical support for its exploration in other indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.